KR20240152915A - 활성제의 경구 투여를 위한 산 중화 중합체를 포함하는 제형 - Google Patents

활성제의 경구 투여를 위한 산 중화 중합체를 포함하는 제형 Download PDF

Info

Publication number
KR20240152915A
KR20240152915A KR1020247031757A KR20247031757A KR20240152915A KR 20240152915 A KR20240152915 A KR 20240152915A KR 1020247031757 A KR1020247031757 A KR 1020247031757A KR 20247031757 A KR20247031757 A KR 20247031757A KR 20240152915 A KR20240152915 A KR 20240152915A
Authority
KR
South Korea
Prior art keywords
composition
receptor
group
acid
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247031757A
Other languages
English (en)
Korean (ko)
Inventor
그레고리 버슈타인
콘스탄틴 이틴
힐렐 갈리처
필립 엠. 슈바르츠
Original Assignee
엔테라 바이오 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔테라 바이오 리미티드 filed Critical 엔테라 바이오 리미티드
Publication of KR20240152915A publication Critical patent/KR20240152915A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247031757A 2022-02-24 2023-02-23 활성제의 경구 투여를 위한 산 중화 중합체를 포함하는 제형 Pending KR20240152915A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313363P 2022-02-24 2022-02-24
US63/313,363 2022-02-24
PCT/IL2023/050192 WO2023161934A1 (en) 2022-02-24 2023-02-23 Formulations comprising acid-neutralizing polymer for oral administration of active agents

Publications (1)

Publication Number Publication Date
KR20240152915A true KR20240152915A (ko) 2024-10-22

Family

ID=87765060

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247031757A Pending KR20240152915A (ko) 2022-02-24 2023-02-23 활성제의 경구 투여를 위한 산 중화 중합체를 포함하는 제형

Country Status (10)

Country Link
US (1) US20250186558A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482507A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506821A (cg-RX-API-DMAC7.html)
KR (1) KR20240152915A (cg-RX-API-DMAC7.html)
CN (1) CN119053335A (cg-RX-API-DMAC7.html)
AU (1) AU2023226618A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251862A1 (cg-RX-API-DMAC7.html)
IL (1) IL315198A (cg-RX-API-DMAC7.html)
MX (1) MX2024010387A (cg-RX-API-DMAC7.html)
WO (1) WO2023161934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
WO2008070543A1 (en) * 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
WO2016128972A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
MX2019001850A (es) * 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
WO2018121702A1 (zh) * 2016-12-30 2018-07-05 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
CN112587496A (zh) * 2020-12-16 2021-04-02 江苏海洋大学 一种艾塞那肽肠溶胶囊及其制备方法

Also Published As

Publication number Publication date
JP2025506821A (ja) 2025-03-13
CN119053335A (zh) 2024-11-29
WO2023161934A1 (en) 2023-08-31
MX2024010387A (es) 2024-09-04
EP4482507A1 (en) 2025-01-01
IL315198A (en) 2024-10-01
US20250186558A1 (en) 2025-06-12
EP4482507A4 (en) 2026-02-18
CA3251862A1 (en) 2023-08-31
AU2023226618A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
JP7736834B2 (ja) 活性薬剤の経口投与のための製剤
US20260124281A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
KR20240150507A (ko) 글루카곤 유사 펩타이드-1 및 이의 유사체의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
AU2023226618A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of active agents
WO2023161938A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide
KR20260061220A (ko) 활성 제제의 경구 투여를 위한 산 중화 중합체성 및 비중합체성 물질의 조합을 포함하는 제형
KR20240145523A (ko) 글루카곤 유사 펩타이드-2의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
WO2025046590A1 (en) Formulations for oral administration of active agents
WO2023161935A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of growth hormone
WO2023161936A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
HK40101653A (en) Formulations for oral administration of active agents
HK40101429A (en) Formulations for oral administration of active agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240924

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application